Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 882 | 888 | 882 | 599 | 761 | - |
Fund Return | -11.75% | -11.18% | -11.75% | -15.71% | -5.32% | - |
Place in category | 166 | 160 | 166 | 140 | 102 | - |
% in Category | 79 | 82 | 79 | 83 | 81 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
JPI Global Income Fund C dist USD h | 18.07B | 8.92 | 1.77 | 4.56 | ||
JPI Global Income Fund C mth USD he | 18.07B | 8.93 | 1.78 | 4.57 | ||
JPI Global Income Fund D acc USD he | 18.07B | 7.82 | 0.75 | 3.52 | ||
JPI Global Income Fund D mth USD he | 18.07B | 7.78 | 0.72 | 3.51 | ||
Global Income Fund C div USD hedged | 18.07B | 8.94 | 1.79 | 4.58 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Franklin Biotech Discovery Nacc | 98.73M | 9.10 | 3.31 | 2.36 | ||
LU0133359157 | 1.37B | 2.18 | 2.28 | 4.73 | ||
Equities L Biotechnology Class I US | 1.37B | 2.92 | 2.58 | 5.59 | ||
Equities L Biotechnology Class R US | 1.37B | 3.48 | 3.56 | 6.05 | ||
Candriam Equities Biotech C USD Cap | 1.37B | 2.56 | 2.68 | 5.20 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Gilead | US3755581036 | 3.55 | 96.95 | +1.42% | |
Vericel Corp Ord | US92346J1088 | 3.55 | 59.25 | +0.46% | |
Bio-Techne | US09073M1045 | 3.38 | 72.76 | +1.29% | |
Novartis | CH0012005267 | 3.32 | 93.80 | +0.39% | |
PTC Therapeutics | US69366J2006 | 3.31 | 46.15 | +2.06% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Neutral | Sell | Strong Sell |
Technical Indicators | BUY | Strong Sell | Strong Sell |
Summary | Neutral | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review